GSK GLOBAL VACCINES CHAIRMAN MONCEF SLAOUI JOINS IAVI BOARD OF DIRECTORS

January 12, 2015

The International AIDS Vaccine Initiative (IAVI) is pleased to announce that Dr. Moncef Slaoui, Chairman, Vaccines, GSK, has joined its Board of Directors.

“Moncef Slaoui brings a wealth of experience in translating promising research into practical vaccines for use throughout the world,” said IAVI President and CEO Margie McGlynn. “His counsel will be crucial to ensuring the support needed to develop a vaccine against HIV/AIDS.” 

Dr. Slaoui joined GSK in 1988. He has held responsibility for R&D since 2006, Vaccines since 2011 and New Product Franchises since 2012. Under his leadership, GSK is partnering with the U.S. National Institutes of Health and others to develop an Ebola vaccine, has submitted a malaria vaccine for regulatory approval, and has brought to market vaccines against infantile gastroenteritis and cervical cancer.

Previously Professor of Immunology at the University of Mons, Belgium, Dr. Slaoui has authored more than 100 scientific papers and presentations. He is a member of the PhRMA and Biotechnology Industry Organization boards and the Advisory Committee to the Director of the National Institutes of Health; an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee. He earned a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine. A citizen of Morocco, Belgium and the United States, he is fluent in English, French and Arabic.

“Vaccines provide a light of hope across the spectrum of infectious diseases,” said Dr. Slaoui. “I am honored to help IAVI continue and expand its important efforts to bring the world a vaccine to help end the enormous suffering and loss wrought by HIV/AIDS.”

IAVI’s distinguished Board of Directors represents an array of global expertise in healthcare, finance, vaccinology, clinical research, international development and academia. Last month, the Board also bid a heartfelt thanks and farewell to longtime members and former chairs Geoffrey Lamb, Chief Economic and Policy Advisor, the Bill & Melinda Gates Foundation, and Paul Klingenstein, Managing Partner, Aberdare Ventures.

“IAVI has benefited enormously from Geoff and Paul’s sage advice, counsel and support,” said McGlynn. “We know they will continue to be passionate advocates for IAVI’s mission and our vision of a world without AIDS.”

Print